What is the CURB‑65 (Confusion, Urea, Respiratory rate, Blood pressure, Age ≥65) scoring system used for assessing community‑acquired pneumonia severity?

CURB-65 Scoring System

CURB-65 is a simple, validated clinical prediction tool developed by the British Thoracic Society that uses five readily available parameters to assess community-acquired pneumonia severity and guide site-of-care decisions, with scores ranging from 0-5 points correlating directly with mortality risk. 1

Score Components

The CURB-65 acronym represents five clinical parameters, with one point assigned for each feature present 1:

• Confusion: Mental test score <8, or new disorientation in person, place, or time 1
• Urea: Blood urea nitrogen >7 mmol/L 1
• Respiratory rate: ≥30 breaths per minute 1
• Blood pressure: Systolic <90 mmHg OR diastolic ≤60 mmHg 1
• Age: ≥65 years 1

Risk Stratification and Management Recommendations

The total score directly correlates with 30-day mortality risk and determines appropriate site of care 1:

• Score 0: 0.7% mortality → Outpatient management 1
• Score 1: 2.1% mortality → Outpatient management 1
• Score 2: 9.2% mortality → Short hospital stay or supervised outpatient care 1
• Score 3: 14.5% mortality → Hospital admission, assess for ICU 1
• Score 4: 40% mortality → Hospital admission, assess for ICU 1
• Score 5: 57% mortality → Hospital admission, assess for ICU 1

Clinical Advantages

CURB-65 offers significant practical advantages over more complex scoring systems like the Pneumonia Severity Index (PSI) 1:

• Requires only simple clinical measures and one laboratory test (blood urea) 1
• Can be calculated rapidly at point of care 1
• A simplified CRB-65 version (omitting urea) can be used when blood testing is unavailable 1
• Validated across multiple international cohorts with consistent performance 2, 3

Performance Characteristics

CURB-65 demonstrates strong predictive accuracy for mortality with an area under the ROC curve of 0.75-0.79 in validation studies 4, 5:

• Sensitivity of 96.7% and specificity of 89.3% for predicting need for intensive care support 5
• Performs comparably to PSI for mortality prediction while being simpler to calculate 1, 4
• Validated for both traditional bacterial CAP and SARS-CoV-2 pneumonia 4

Important Clinical Caveats

CURB-65 has recognized limitations that require clinical judgment to override the score when appropriate 1:

• May underestimate severity in young patients without comorbidities who develop severe respiratory failure 1
• May underestimate risk in elderly patients with significant comorbidities 1
• Does not capture hypoxia as a severity marker 1
• Sensitivity of only 78.4% for predicting need for critical care interventions means some high-risk patients score low 6
• Among patients with CURB-65 ≤2,15.6% still required ICU admission and 6.4% received critical care interventions 6

Clinical Application

The American Thoracic Society/IDSA guidelines recommend using CURB-65 as an adjunct to clinical judgment, not as a replacement for physician assessment 1:

• Scores of 0-1 reliably identify low-risk patients suitable for outpatient management 1
• Scores ≥3 indicate severe pneumonia requiring hospitalization with ICU assessment 1
• External factors including comorbidities, social circumstances, failure of outpatient therapy, and ability to obtain medications should influence final disposition decisions 1
• The 2019 ATS/IDSA guidelines provide conditional recommendation for CURB-65 use given its simplicity, though PSI has stronger evidence for effectiveness 1